首页> 外文期刊>Leukemia and lymphoma >The impact of Agent Orange exposure on prognosis and management in patients with chronic lymphocytic leukemia: a National Veteran Affairs Tumor Registry Study
【24h】

The impact of Agent Orange exposure on prognosis and management in patients with chronic lymphocytic leukemia: a National Veteran Affairs Tumor Registry Study

机译:药剂橙暴露对慢性淋巴细胞白血病患者预后和管理的影响:全国老兵事务肿瘤登记研究

获取原文
获取原文并翻译 | 示例
           

摘要

Exposure to Agent Orange (AO) has been associated with the development of chronic lymphocytic leukemia (CLL). We performed a retrospective study of 2052 Vietnam veterans identified in the National VA Tumor Registry to assess the impact of AO exposure on CLL prognosis, treatment and survival. Prognostic factors did not differ based on exposure. Veterans exposed to AO were diagnosed younger (63.2 vs. 70.5 years, p.0001) and had longer overall survival (median not reached vs. 91 months, p.001). This prolonged survival was in the subgroups of patients aged 60-69 years (p.0001) and those with 11q deletion (p.0001). Those exposed to AO were more likely to be treated with fludarabine, chlorambucil and rituximab (38 vs. 21%, p.001) and bendamustine plus rituximab (25 vs. 18%, p=0.039) as first line therapy. Exposure to AO was not associated with either poor prognostic factors or shortened overall survival in our large veteran population with CLL.
机译:暴露于药剂橙(AO)与慢性淋巴细胞白血病(CLL)的发育有关。 我们对国家VA肿瘤登记处确定了2052名越南退伍军人的回顾性研究,以评估AO暴露对CLL预后,治疗和生存的影响。 预后因子没有根据暴露而不同。 暴露于AO的退伍军人被诊断出来(63.2与70.5岁,P& .0001),并且整体生存率更长(中位数未达到91个月,P& .001)。 这种延长的存活率是60-69岁患者的亚组(P& .0001)和11q删除的患者(p& .0001)。 暴露于AO的那些更容易用氟氮滨,氯镁蛋白和利妥昔单抗(38 vs.21%,P&。001)和苯匹斯汀加里妥昔单抗(25 vs.18%,p = 0.039)作为第一线疗法治疗。 暴露于AO与差的预后因素无关或缩短我们的大型退伍军人人群的整体生存与CLL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号